Ma Teng, Tran Tuyen Ba, Lin Ethan, Hunt Stephanie, Haveman Riley, Castro Kylie, Lu Jianqin
Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, the University of Arizona, Tucson 85721, AZ, USA.
Clinical and Translational Oncology Program, the University of Arizona Cancer Center, Tucson 85721, AZ, USA.
Acta Pharm Sin B. 2025 Feb;15(2):834-851. doi: 10.1016/j.apsb.2024.11.012. Epub 2024 Nov 25.
The size of nanodrugs plays a crucial role in shaping their chemical and physical characteristics, consequently influencing their therapeutic and diagnostic interactions within biological systems. The optimal size of nanomedicines, whether small or large, offers distinct advantages in disease treatment, creating a dilemma in the selection process. Addressing this challenge, size-transformable nanodrugs have surfaced as a promising solution, as they can be tailored to entail the benefits associated with both small and large nanoparticles. In this review, various strategies are summarized for constructing size-transformable nanosystems with a focus on nanotherapeutic applications in the field of biomedicine. Particularly we highlight recent research developments in cancer therapy. This review aims to inspire researchers to further develop various toolboxes for fabricating size-transformable nanomedicines for improved intervention against diverse human diseases.
纳米药物的尺寸在塑造其化学和物理特性方面起着至关重要的作用,从而影响它们在生物系统中的治疗和诊断相互作用。纳米药物的最佳尺寸,无论是小尺寸还是大尺寸,在疾病治疗中都具有独特的优势,这在选择过程中造成了两难困境。为应对这一挑战,尺寸可转变的纳米药物已成为一种有前景的解决方案,因为它们可以进行定制,兼具与小尺寸和大尺寸纳米颗粒相关的优势。在这篇综述中,总结了构建尺寸可转变纳米系统的各种策略,重点是生物医学领域的纳米治疗应用。特别值得一提的是,我们突出了癌症治疗方面的最新研究进展。这篇综述旨在激励研究人员进一步开发各种工具包,以制造尺寸可转变的纳米药物,从而更好地干预各种人类疾病。
Acta Pharm Sin B. 2025-2
Cochrane Database Syst Rev. 2014-4-29
2025-1
2025-1
Cochrane Database Syst Rev. 2022-5-20
Curr Issues Mol Biol. 2025-6-14
Nat Cancer. 2024-3
Chem Rev. 2023-9-27
Acta Pharm Sin B. 2023-7
Proc Natl Acad Sci U S A. 2022-11-8
Acc Chem Res. 2022-6-21
Adv Drug Deliv Rev. 2022-4